A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection

• Drug: PF-00868554
  
  500 mg BID administered as 5x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks.
• Drug: PF-00868554
  
  300 mg BID administered as 3x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
• Drug: PF-00868554
  
  200 mg BID administered as 2x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
• Drug: Placebo
  
  Placebo administered for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks

• Experimental: A
  
  500 mg BID
  Intervention: Drug: PF-00868554
• Experimental: B
  
  300 mg BID
  Intervention: Drug: PF-00868554
• Experimental: C
  
  200 mg BID
  Intervention: Drug: PF-00868554
• Placebo Comparator: D
  
  Placebo
  Intervention: Drug: Placebo

Inclusion Criteria:

• Treatment naive (no prior treatment with IFN-a +/- RBV regimens.
• Subjects who have discontinued IFN-a containing regimens after <2 weeks of therapy due to tolerability issues are considered treatment naive.
• HCV RNA > 100,000 IU/mL at screening.
• Genotype 1.
• A diagnosis of chronic HCV infection for at least 6 months.

Exclusion Criteria:

• Evidence of acute or chronic infection with HIV or HBV.
• Exposure within the previous three months to an investigational anti-HCV agent.
• Evidence of severe or decompensated liver disease.
• Subjects with liver disease unrelated to HCV infection.